Crossmark

Rigor prophylaxis in stage IV melanoma and renal cell carcinoma patients treated with high dose IL-2

Crossref DOI link: https://doi.org/10.1186/s12885-018-4810-y

Published Online: 2018-10-20

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Khong, Brian

Lawson, Benjamin O.

Ma, Junjie

McGovern, Cheryl

Van Atta, Joan K.

Ray, Abhijit

Khong, Hung T. https://orcid.org/0000-0001-8365-957X
License Information

Text and Data Mining valid from 2018-10-20
More Information

Article History

Received: 29 September 2017

Accepted: 12 September 2018

First Online: 20 October 2018

Ethics approval and consent to participate

: Ethics approval and consent were formally waived by the University of Utah Institutional Review Board (ethics committee).

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.